Meta Ordered to Pay $567M Over Child Safety Violations in New Mexico 
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium 
DHL Q2 Profit Jumps 24% as Express Business Drives Growth 
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook 
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
OpenAI Restricts Astra AI Over Cyberattack Risks 
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth 
SpaceX Targets Starship Flight 14 With First V3 Starlink Satellite Launch 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
GAITHERSBURG, Md., March 05, 2018 -- OpGen, Inc. (NASDAQ:OPGN) announced today that the Company will report its fourth quarter and fiscal year 2017 financial results after close of market on Thursday, March 15, 2018. OpGen’s management team will host a live conference call and webcast at 4:30 p.m. Eastern time to discuss the Company’s financial results and business progress.
Dial-in Information
U.S. Dial-In Number: (888) 883-4599
International Dial-In Number: (484) 653-6821
Conference ID: 8899787
Replay Dial-in Information
U.S. Dial-In Number: (855) 859-2056
International Dial-In Number: (404) 537-3406
Conference ID: 8899787
Following the conclusion of the conference call, a replay will be available through March 22, 2018. The live, listen-only webcast of the conference call may also be accessed by visiting the investors section of the Company’s website at http://ir.opgen.com. A replay of the webcast will be available after the conclusion of the call and will be archived on the Company’s website for 90 days.
About OpGen
OpGen, Inc. is harnessing the power of informatics and genomic analysis to provide complete solutions for patient, hospital and network-wide infection treatment and prevention. Learn more at www.opgen.com and follow OpGen on Twitter and LinkedIn.
OpGen, Acuitas, and Acuitas Lighthouse are registered trademarks of OpGen, Inc. All other trademarks are properties of their respective owners.
OpGen Contact:
Michael Farmer
Sr. Director, Marketing
240-813-1284
[email protected]
[email protected]
Investor Contacts:
LHA Investor Relations
Kim Sutton Golodetz
212-838-3777
[email protected]
or
Bruce Voss
310-691-7100
[email protected]
